Breast cancerBCCAR T cell therapyMahidol UniversityNational Research Council of ThailandDual BATs
…Background Breast cancer (BC) is the most common cancer among women worldwide and remain…
23,712articles mentioning diseases
125,551disease mentions
18,081distinct diseases extracted
0%of mentions human-reviewed
All extracted diseases
Showing 601–660 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.
Hypertensive disorders of pregnancy12respiratory distress syndrome12Functional Neurological Disorder (FND)12Gestational diabetes mellitus (GDM)12Pleural Mesothelioma12inflammatory arthritis12Infectious disease12Malignancies12Respiratory infections12Rheumatic Heart Disease12Juvenile systemic sclerosis12Large vessel occlusion (LVO) stroke12Oesophageal adenocarcinoma12Spinal Cord Injury12Systemic sclerosis-associated interstitial lung disease (SSc-ILD)12Transient ischaemic attack12Urinary tract infections12colorectal12infections12relapsing-remitting multiple sclerosis12CRPS11MetS11SDH11IS11HTN11CM11ICAS11HPV11PM11Hepatitis11Osteopenia11Pericarditis11Chronic insomnia11AIDS11Glioma11Psychiatric disorders11Hodgkin lymphoma11Overweight and obesity11Childhood Cancer11ROP11Sleep apnoea11Postoperative pain11Carotid artery stenosis11Dysphagia11Ewing Sarcoma11Bulimia Nervosa11Rhabdomyolysis11choledocholithiasis11In-Stent Restenosis11overweight or obesity11LBP11SLE-related11Frontotemporal Dementia11Graves’ disease11NCDs11asthma-related11Acute liver failure11Cerebral aneurysms11Inflammatory bowel diseases11Lower respiratory tract infections11
Articles mentioning diseases
23,712 articles · page 432 of 1976colorectal cancerpancreatic cancerPDACCRChuman cancerAZD0240TCR-T cell therapy
…uency, occurring in 28% and 12% of pancreatic cancer (PDAC) and colorectal cancer (CRC), respectively. KRAS G12D-containing peptides are presente…
93.5%
NSCLCmetastatic melanomaStage IV non-small cell lung cancerStage IV melanomaSARS-COV-2 mRNA vaccinesMD Anderson Cancer Center
…ociated with a near doubling of OS among patients with Stage IV NSCLC (555 days vs 1120 days, adj HR 0.5, 95% CI 0.4-0.7) and Stage I…
94.8%
melanomaUniversity of California IrvinenivolumabChao Family Comprehensive Cancer CenteripilimumabPD-1 immunotherapyαPD-1
… approval in 2014 but still fails in the majority of metastatic melanoma patients, emphasizing the need to further understand its impact…
stage IIB/C melanomastage IIB/IIC melanomastage IIB/C diseasestage IIB or IIC melanomaPembrolizumabFDAadjuvant immunotherapy
…, 32% of patients in the US received adjuvant immunotherapy for stage IIB/C melanoma and 21% within our healthcare system. The limited dissemination…
colorectal cancerCRCNivolumabNivoWCG Institutional Review Board
…(Nivo) is an anti-PD-1 immune checkpoint inhibitor approved for colorectal cancer (CRC), yet responses are highly variable between patients, and …
CRCMSS CRCWest China Hospital of Sichuan UniversityAkkInstitutional Review BoardimmunotherapyClinicalTrials.gov
…MSS CRC.Methods Preclinical studies used CT26 mouse models (MSS CRC) with oral Akk administration to assess tumor growth effects. T…
MSS mCRCMSS CRCMSS rectal canceratezolizumabvilastobartXTX101
…lizumab (1200mg Q3W) in heavily pretreated patients (n=44) with MSS mCRC, including 27 with non liver metastases (NLM). In an explorator…
myeloid leukemiaPROCPlatinum resistant ovarian cancerplatinum-resistant ovarian cancerovarian cancerECOG Performance StatusDana-Farber Cancer InstitutePHASE ONE FoundationIL-12IL-15+6 more
…ry-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. Sep 21 2016;8(357):357ra123. doi:10.1126/scitr…
oral head and neck squamous cell carcinomamelanomathyroid cancersolid tumorsAGX-148Providence Institutional Review BoardClinicalTrials.govlymphodepleting chemotherapy
…bserved in solid tumors including melanoma, thyroid cancer, and oral head and neck squamous cell carcinoma with responses lasting over 600 days in some patients. TCR sequ…
melanomanivolumabRP1Vusolimogene oderparepvecanti-PD-1 therapy
… review, and overall survival (OS) in patients with BRAF-mutant melanoma, stratified by prior BRAFi treatment (data cutoff: March 8, 202…
NeuroblastomaTemozolomideIrinotecandinutuximabaCD40University of Wisconsin
…Background Neuroblastoma is the most common pediatric solid cancer, outside of brain can…